Evidence map›Paper›PMID 32326143›Full record

ArticleBiomolecules2020

New Therapeutic Strategies for Osteoarthritis by Targeting Sialic Acid Receptors.

Paula Carpintero-Fernandez, Marta Varela-Eirin, Alessandra Lacetera, Raquel Gago-Fuentes, Eduardo Fonseca, Sonsoles Martin-Santamaria, Maria D Mayan

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Exploring serumHeliyon · 2024
    Article
  4. Article
  5. Review
  6. High-ResolutionAnalytical chemistry · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Paula Carpintero-FernandezCellCOM Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), CH-Universitario A Coruña (XXIAC), Universidade da Coruña (UDC), Servizo Galego de Saúde (SERGAS), Xubias de Arriba, 84, 15006 A Coruña, Spain.
Marta Varela-EirinCellCOM Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), CH-Universitario A Coruña (XXIAC), Universidade da Coruña (UDC), Servizo Galego de Saúde (SERGAS), Xubias de Arriba, 84, 15006 A Coruña, Spain.
Alessandra LaceteraDepartment of Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas CIB-CSIC, C/Ramiro de Maeztu, 9, 28040 Madrid, Spain.
Raquel Gago-FuentesCellCOM Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), CH-Universitario A Coruña (XXIAC), Universidade da Coruña (UDC), Servizo Galego de Saúde (SERGAS), Xubias de Arriba, 84, 15006 A Coruña, Spain.
Eduardo FonsecaCellCOM Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), CH-Universitario A Coruña (XXIAC), Universidade da Coruña (UDC), Servizo Galego de Saúde (SERGAS), Xubias de Arriba, 84, 15006 A Coruña, Spain.ORCID 0000-0002-8048-2681
Sonsoles Martin-SantamariaDepartment of Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas CIB-CSIC, C/Ramiro de Maeztu, 9, 28040 Madrid, Spain.ORCID 0000-0002-7679-0155
Maria D MayanCellCOM Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), CH-Universitario A Coruña (XXIAC), Universidade da Coruña (UDC), Servizo Galego de Saúde (SERGAS), Xubias de Arriba, 84, 15006 A Coruña, Spain.
Universidade da Coruña · ESCentro de Investigaciones Biológicas Margarita Salas · ES

Funding

Instituto de Salud Carlos III PI13/00591Instituto de Salud Carlos III PI16/00035Ministerio de Economía, Industria y Competitividad, Gobierno de España CTQ2017-88353-RSociedad Española de Reumatología FER-2013Spanish Society for Research on Bone and Mineral Metabolism FEIOMM-2016
6 · The paper itself

Abstract

Osteoarthritis (OA) is the most common degenerative joint disease characterized by articular cartilage degradation and joint degeneration. The articular cartilage is mainly formed by chondrocytes and a collagen-proteoglycan extracellular matrix that contains high levels of glycosylated proteins. It was reported that the shift from glycoproteins containing α-2,6-linked sialic acids to those that contain α-2,3 was associated with the onset of common types of arthritis. However, the pathophysiology of α-2,3-sialylation in cartilage has not been yet elucidated. We show that cartilage from osteoarthritic patients expresses high levels of the α-2,3-sialylated transmembrane mucin receptor, known as podoplanin (PDPN). Additionally, the

Indexed as

AnimalsCartilage, ArticularCells, CulturedChondrocytesExtracellular MatrixFemaleGlycoproteinsHumansLectinsMaleMembrane GlycoproteinsMice, Inbred BALB CModels, MolecularN-Acetylneuraminic AcidNF-kappa BOsteoarthritisGlycoproteinsLectinsMembrane GlycoproteinsN-Acetylneuraminic AcidNF-kappa BPDPN protein, humanPodoplaninProtein IsoformsReceptors, Cell Surfacesialic acid receptorarthritisarticular chondrocytecartilageglycoproteinsMASLmolecular modellingosteoarthritispodoplaninsialylation

Identifiers

PMID32326143
PMCPMC7226619
OpenAlexW3020362410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.